Vertex Pharmaceutic (VRTX) 88.96 $VRTX
Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 62.10 (-0.64), BIIB: 251.30 (+4.03), VRTX: 88.96 (-1.09), GILD: 86.55 (+1.08), UNH: 141.27 (+0.47), MRK: 59.35 (+0.57), ALXN: 124.42 (+1.08), XOM: 93.54 (+0.58), CVX: 104.77 (+1.72), REGN: 378.35 (+6.90), CELG: 105.03 (+0.62)
Vertex Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 3.12%
Comtex SmarTrend(R) - Wed Jul 06, 2:51PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $85.92 to a high of $89.90. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $88.46 on volume of 546,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 88.96 (-1.09)
After Yesterday's Rally of 3.12% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jul 06, 2:49PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $85.92 to a high of $89.90. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $88.46 on volume of 546,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 88.96 (-1.09)
Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mRNA Therapeutics(TM) for Cystic Fibrosis
BusinessWire - Wed Jul 06, 7:14AM CDT
---Moderna to receive $40 million upfront, made up of a $20 million cash payment and a $20 million convertible note investment, with potential for up to additional $275 million in milestones plus royalty payments-
VRTX: 88.96 (-1.09)
Look for Shares of Vertex Pharmaceuticals to Potentially Pullback after Yesterday's 1.56% Rise
Comtex SmarTrend(R) - Fri Jul 01, 3:27PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $85.17 to a high of $88.46. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $86.64 on volume of 457,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 88.96 (-1.09)
Zacks.com featured highlights: Antero Resources, ZELTIQ Aesthetics, Vertex Pharmaceuticals, ViaSat and Lumos Networks
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 8:30AM CDT
Zacks.com featured highlights: Antero Resources, ZELTIQ Aesthetics, Vertex Pharmaceuticals, ViaSat and Lumos Networks
VRTX: 88.96 (-1.09), AR: 25.70 (+0.24), ZLTQ: 29.34 (+0.58), LMOS: 12.56 (+0.11), VSAT: 73.64 (+2.62)
How Does Brexit Impact Healthcare Stocks?
Arpita Dutt - Zacks Investment Research - Mon Jun 27, 8:34AM CDT
While Brexit does create economic uncertainty and there could be some near-term volatility in the sector, the general verdict is that Brexit's impact on drug stocks will be limited.
VRTX: 88.96 (-1.09), BMRN: 91.49 (+3.33), ALXN: 124.42 (+1.08), GSK: 43.38 (+0.04), CELG: 105.03 (+0.62)
Dump These 5 Toxic Stocks to Avoid Portfolio Bleeding
Zacks Equity Research - Zacks Investment Research - Mon Jun 27, 8:22AM CDT
Investing in a stock whose current valuation exceeds its true inherent potential, is bound to result in loss over time.
AR: 25.70 (+0.24), VRTX: 88.96 (-1.09), ZLTQ: 29.34 (+0.58), LMOS: 12.56 (+0.11), VSAT: 73.64 (+2.62)
How These Biotech's Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma
PR Newswire - Thu Jun 23, 6:30AM CDT
The Biotechnology industry might still be in rough waters, but it continues to present great opportunities to investors. Stock-Callers.com assesses the recent performances of our featured companies for today: Intrexon Corp. (NYSE: XON), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Learn more about these stocks and receive your complimentary trade alerts at:
VRTX: 88.96 (-1.09), XON: 26.72 (+0.83), ARNA: 1.70 (+0.06), REGN: 378.35 (+6.90)
Claire's Place Foundation Receives Grant From Vertex Pharmaceuticals
GlobeNewswire - Wed Jun 22, 2:07AM CDT
Claire's Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis, is proud to announce that Vertex Pharmaceuticals Incorporated has awarded the foundation with a grant to support their Extended Hospital Stay Fund.
VRTX: 88.96 (-1.09)
Vertex Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.28%
Comtex SmarTrend(R) - Thu Jun 16, 2:35PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $88.58 to a high of $90.42. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $89.52 on volume of 568,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 88.96 (-1.09)
Vertex Pharmaceuticals Falls 1.28% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jun 16, 2:34PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $88.58 to a high of $90.42. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $89.52 on volume of 568,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 88.96 (-1.09)
Vertex Announces Presentations of Data for KALYDECO(R) (ivacaftor) and ORKAMBI(R) (lumacaftor/ivacaftor) at European Cystic Fibrosis Society (ECFS) Conference
BusinessWire - Fri Jun 10, 10:02AM CDT
---Data from Phase 3 safety study of ORKAMBI in children ages 6-11 presented today at ECFS-
VRTX: 88.96 (-1.09)
Vertex Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 2.07%
Comtex SmarTrend(R) - Thu Jun 09, 3:17PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $92.18 to a high of $94.55. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $92.47 on volume of 421,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 88.96 (-1.09)
After Yesterday's Decline of 2.07%, Vertex Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Thu Jun 09, 3:15PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $92.18 to a high of $94.55. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $92.47 on volume of 421,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 88.96 (-1.09)
5 Toxic Stocks to Discard from Your Portfolio Right Now
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 7:27AM CDT
Identifying toxic stocks on a regular basis and removing them from one's portfolio is a secret to investing success.
VRTX: 88.96 (-1.09), ZLTQ: 29.34 (+0.58), ULTI: 215.80 (+1.35), LGF: 19.10 (+0.26), CRM: 80.89 (+2.13)
Stock Market News for June 08, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:10AM CDT
Benchmarks closed mostly in the green on Tuesday following gains in energy stocks
BIIB: 251.30 (+4.03), VRTX: 88.96 (-1.09), PXD: 153.72 (+4.49), ALXN: 124.42 (+1.08), HAL: 45.03 (+1.48), EOG: 82.54 (+0.93), AMGN: 161.10 (+4.51), ILMN: 141.25 (+1.19), XOM: 93.54 (+0.58), COP: 42.30 (+0.79), JUNO: 27.81 (-13.01), CVX: 104.77 (+1.72), OXY: 76.13 (+0.68), REGN: 378.35 (+6.90)
Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Jun 01, 1:40PM CDT
With the annual meeting of ASCO coming up, watch out for updates from several biotech companies on their cancer treatments.
BIIB: 251.30 (+4.03), VRTX: 88.96 (-1.09), GILD: 86.55 (+1.08), SRPT: 22.62 (+1.70), ICPT: 151.73 (+7.98), ABBV: 64.16 (+0.73), IONS: 25.36 (+0.22)
Vertex (VRTX) Orkambi sNDA Accepted with Priority Review
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:28AM CDT
Vertex (VRTX) announced that the FDA has accepted an sNDA for Orkambi for the treatment of CF, in children (aged 6 to 11 years) who have two copies of the F508del mutation.
VRTX: 88.96 (-1.09), ANIP: 56.51 (-1.61), PFE: 36.12 (+0.35), BMY: 75.28 (+1.20)
Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 62.10 (-0.64), BIIB: 251.30 (+4.03), VRTX: 88.96 (-1.09), GILD: 86.55 (+1.08), UNH: 141.27 (+0.47), MRK: 59.35 (+0.57), ALXN: 124.42 (+1.08), XOM: 93.54 (+0.58), CVX: 104.77 (+1.72), REGN: 378.35 (+6.90), CELG: 105.03 (+0.62)
Vertex Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 3.12%
Comtex SmarTrend(R) - Wed Jul 06, 2:51PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $85.92 to a high of $89.90. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $88.46 on volume of 546,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 88.96 (-1.09)
After Yesterday's Rally of 3.12% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jul 06, 2:49PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $85.92 to a high of $89.90. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $88.46 on volume of 546,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 88.96 (-1.09)
Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mRNA Therapeutics(TM) for Cystic Fibrosis
BusinessWire - Wed Jul 06, 7:14AM CDT
---Moderna to receive $40 million upfront, made up of a $20 million cash payment and a $20 million convertible note investment, with potential for up to additional $275 million in milestones plus royalty payments-
VRTX: 88.96 (-1.09)
Look for Shares of Vertex Pharmaceuticals to Potentially Pullback after Yesterday's 1.56% Rise
Comtex SmarTrend(R) - Fri Jul 01, 3:27PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $85.17 to a high of $88.46. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $86.64 on volume of 457,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 88.96 (-1.09)
Zacks.com featured highlights: Antero Resources, ZELTIQ Aesthetics, Vertex Pharmaceuticals, ViaSat and Lumos Networks
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 8:30AM CDT
Zacks.com featured highlights: Antero Resources, ZELTIQ Aesthetics, Vertex Pharmaceuticals, ViaSat and Lumos Networks
VRTX: 88.96 (-1.09), AR: 25.70 (+0.24), ZLTQ: 29.34 (+0.58), LMOS: 12.56 (+0.11), VSAT: 73.64 (+2.62)
How Does Brexit Impact Healthcare Stocks?
Arpita Dutt - Zacks Investment Research - Mon Jun 27, 8:34AM CDT
While Brexit does create economic uncertainty and there could be some near-term volatility in the sector, the general verdict is that Brexit's impact on drug stocks will be limited.
VRTX: 88.96 (-1.09), BMRN: 91.49 (+3.33), ALXN: 124.42 (+1.08), GSK: 43.38 (+0.04), CELG: 105.03 (+0.62)
Dump These 5 Toxic Stocks to Avoid Portfolio Bleeding
Zacks Equity Research - Zacks Investment Research - Mon Jun 27, 8:22AM CDT
Investing in a stock whose current valuation exceeds its true inherent potential, is bound to result in loss over time.
AR: 25.70 (+0.24), VRTX: 88.96 (-1.09), ZLTQ: 29.34 (+0.58), LMOS: 12.56 (+0.11), VSAT: 73.64 (+2.62)
How These Biotech's Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma
PR Newswire - Thu Jun 23, 6:30AM CDT
The Biotechnology industry might still be in rough waters, but it continues to present great opportunities to investors. Stock-Callers.com assesses the recent performances of our featured companies for today: Intrexon Corp. (NYSE: XON), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Learn more about these stocks and receive your complimentary trade alerts at:
VRTX: 88.96 (-1.09), XON: 26.72 (+0.83), ARNA: 1.70 (+0.06), REGN: 378.35 (+6.90)
Claire's Place Foundation Receives Grant From Vertex Pharmaceuticals
GlobeNewswire - Wed Jun 22, 2:07AM CDT
Claire's Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis, is proud to announce that Vertex Pharmaceuticals Incorporated has awarded the foundation with a grant to support their Extended Hospital Stay Fund.
VRTX: 88.96 (-1.09)
Vertex Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.28%
Comtex SmarTrend(R) - Thu Jun 16, 2:35PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $88.58 to a high of $90.42. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $89.52 on volume of 568,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 88.96 (-1.09)
Vertex Pharmaceuticals Falls 1.28% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jun 16, 2:34PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $88.58 to a high of $90.42. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $89.52 on volume of 568,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 88.96 (-1.09)
Vertex Announces Presentations of Data for KALYDECO(R) (ivacaftor) and ORKAMBI(R) (lumacaftor/ivacaftor) at European Cystic Fibrosis Society (ECFS) Conference
BusinessWire - Fri Jun 10, 10:02AM CDT
---Data from Phase 3 safety study of ORKAMBI in children ages 6-11 presented today at ECFS-
VRTX: 88.96 (-1.09)
Vertex Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 2.07%
Comtex SmarTrend(R) - Thu Jun 09, 3:17PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $92.18 to a high of $94.55. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $92.47 on volume of 421,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 88.96 (-1.09)
After Yesterday's Decline of 2.07%, Vertex Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Thu Jun 09, 3:15PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $92.18 to a high of $94.55. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $92.47 on volume of 421,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 88.96 (-1.09)
5 Toxic Stocks to Discard from Your Portfolio Right Now
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 7:27AM CDT
Identifying toxic stocks on a regular basis and removing them from one's portfolio is a secret to investing success.
VRTX: 88.96 (-1.09), ZLTQ: 29.34 (+0.58), ULTI: 215.80 (+1.35), LGF: 19.10 (+0.26), CRM: 80.89 (+2.13)
Stock Market News for June 08, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:10AM CDT
Benchmarks closed mostly in the green on Tuesday following gains in energy stocks
BIIB: 251.30 (+4.03), VRTX: 88.96 (-1.09), PXD: 153.72 (+4.49), ALXN: 124.42 (+1.08), HAL: 45.03 (+1.48), EOG: 82.54 (+0.93), AMGN: 161.10 (+4.51), ILMN: 141.25 (+1.19), XOM: 93.54 (+0.58), COP: 42.30 (+0.79), JUNO: 27.81 (-13.01), CVX: 104.77 (+1.72), OXY: 76.13 (+0.68), REGN: 378.35 (+6.90)
Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Jun 01, 1:40PM CDT
With the annual meeting of ASCO coming up, watch out for updates from several biotech companies on their cancer treatments.
BIIB: 251.30 (+4.03), VRTX: 88.96 (-1.09), GILD: 86.55 (+1.08), SRPT: 22.62 (+1.70), ICPT: 151.73 (+7.98), ABBV: 64.16 (+0.73), IONS: 25.36 (+0.22)
Vertex (VRTX) Orkambi sNDA Accepted with Priority Review
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:28AM CDT
Vertex (VRTX) announced that the FDA has accepted an sNDA for Orkambi for the treatment of CF, in children (aged 6 to 11 years) who have two copies of the F508del mutation.
VRTX: 88.96 (-1.09), ANIP: 56.51 (-1.61), PFE: 36.12 (+0.35), BMY: 75.28 (+1.20)
